Navigation Links
Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market

EXTON, Pa., April 10 /PRNewswire/ -- On April 8th, 2009, Genentech and Roche announced the voluntary withdrawal of Raptiva (efalizumab, marketed by Genentech/Roche and Xoma) from the US market. The withdrawal comes after recent post-marketing reports of PML associated with Raptiva treatment.

BioTrends will field its fourth annual TreatmentTrends(TM): Psoriasis survey on April 13th with a special section dedicated to the impact of the Raptiva withdrawal. The on-line survey will be completed by 150 clinical dermatologists and is structured to assess treatment prevalence and brand use for topical, oral, and biologic agents. A comprehensive attribute analysis is provided for each class to indicate areas of unmet need and market share projections for the next six months. In addition, awareness and interest in products in late stage development, such as Centocor's STELARA (ustekinumab) and Abbott's ABT-874 is assessed. The report will be published in early May.

A second report offered by BioTrends, ChartTrends(TM): Biologics in Psoriasis, is a report that is based on actual patient level audit data collected through a proprietary audit tool. In this report, 1000 patients who are currently being treated with biologic agents will be reviewed to analyze the treatment algorithm that culminates in the use of biologic agents, patient demographics/co-morbidities associated with specific biologic brand use, product switching incidence and rationale, and concomitant medications. A special section focused on switches from Raptiva will be included to understand if these patients migrate to other biologic brands or are discontinued altogether from biologic therapy. This report will be published in early June.

According to last year's TreatmentTrends(TM): Psoriasis report, market share for Raptiva had steadily declined since 2006 and only 44% of the dermatologists surveyed were using the product in their practices in April 2008. Amgen/Wyeth's Enbrel and Abbott's Humira, the most frequently prescribed biologics in psoriasis, were rated significantly higher than Raptiva on nearly all of the most important attributes. However, Raptiva held a competitive advantage over all biologic competitors on its efficacy in palmo-plantar psoriasis.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. ( provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
2. UD researchers race ahead with latest spintronics achievement
3. Digital Healthcare Announces Cincinnati Eye Institute is Latest Retasure Reading Center
4. 49th Annual Meeting of the American Society of Hematology Will Feature the Latest Research in Blood Diseases
5. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
6. PacifiCare Capitulates to Latest Patient Revolt
7. Parks Associates Digital Health Analyst to Present Latest Research and Forecasts at ATA Show
8. Carbon nanotube measurements: latest in NIST how-to series
9. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
10. [video] Jacques Tizabi, CEO of Universal Detection Technology Discusses Latest Purchase Order on WallSt.nets 3-Minute Press Show
11. Latest Sleep Disorder Technology Tested With SleepQuest
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) today announced ... Section Award. Presented annually since 1961, the USGA Green Section Award recognizes an individual’s ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology ...
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... ... 2015 , ... This fall, global software solutions leader SAP and AdVenture Capital ... and pitch their BIG ideas to improve health and wellness in their schools. , ... win the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a global ... it has released a new version of its ... North America have already installed ... also includes a FIDO UAF certified server component ... preparing to activate FIDO features. These customers include some ...
Breaking Biology News(10 mins):